EcoDrugPlus

Phosphodiesterase 4b

Ensembl ID : ENSOKIG00005018326
Gene Symbol: PDE4B
3 Cross references
219 Possible Orthologues:

Phosphodiesterase 4d

Ensembl ID : ENSOKIG00005017188
Gene Symbol: PDE4D
3 Cross references
213 Possible Orthologues:

Phosphodiesterase 4d

Ensembl ID : ENSOKIG00005013730
Gene Symbol: PDE4D
3 Cross references
212 Possible Orthologues:

Phosphodiesterase 4d

Ensembl ID : ENSOKIG00005044709
Gene Symbol: PDE4D
3 Cross references
213 Possible Orthologues:

Phosphodiesterase 7a

Ensembl ID : ENSOKIG00005036265
Gene Symbol: PDE7A
3 Cross references
174 Possible Orthologues:

Phosphodiesterase 7a

Ensembl ID : ENSOKIG00005024240
Gene Symbol: PDE7A
3 Cross references
169 Possible Orthologues:

Phosphodiesterase 9a

Ensembl ID : ENSOKIG00005008983
Gene Symbol: PDE9A
1 Cross references
179 Possible Orthologues:

Phosphodiesterase 9a

Ensembl ID : ENSOKIG00005016655
Gene Symbol: PDE9A
3 Cross references
179 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 1

Ensembl ID : ENSOKIG00005008470
Gene Symbol: PIK3R1
3 Cross references
53 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 1

Ensembl ID : ENSOKIG00005047469
Gene Symbol: PIK3R1
3 Cross references
196 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 2

Ensembl ID : ENSOKIG00005032559
Gene Symbol: PIK3R2
3 Cross references
185 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 2

Ensembl ID : ENSOKIG00005014155
Gene Symbol: PIK3R2
1 Cross references
185 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).